jRCT2080225106已完成3 期
A Phase 3, Randomized, Double blind, Placebo controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intolerant to Biologic DMARD Therapy
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 390
- 试验地点
- 1
- 主要终点
- ACR20 response
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Randomized, Parallel Assignment, Double blind, Treatment
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 18age old over 至 75age old under（—）
- 性别
- All
入选标准
- •Male or female participants who are 18-75 years of age (20-75 years of age at sites in Japan), on the day of signing initial informed consent
- •Meet Classification Criteria for Psoriatic Arthritis (CASPAR)
- •Have a history consistent with PsA 6 months or more at Screening Have active PsA defined as 3 or more swollen joints (from a 66 swollen joint count [SJC]) and 3 or more tender joints (from a 68 tender joint count [TJC]) at Screening and Day 1; these may or may not be the same joints at Screening and Day 1
- •Must have a documented history or active signs of at least one of the following at Screening
- •a) Plaque psoriasis
- •b) Nail changes attributed to psoriasis
- •Have had inadequate response (lack of efficacy after 12 weeks or more duration of therapy) or intolerance to at least one and not more than 3 bioDMARDs administered for the treatment of PsA or psoriasis, as per local guidelines / standard of care
- •Prior to the first dose of study drug on Day 1, treatment with bioDMARD(s) should have been discontinued
排除标准
- •Prior exposure to a JAK inhibitor > 2 doses
- •Any active / recent infection
- •Any chronic and / or uncontrolled medical condition that would put the subject at increased risk during study participation or circumstances which may make a subject unlikely or unable to complete or comply with study procedures and requirements, per investigator judgement
- •Any moderately to severely active musculoskeletal or skin disorder other than PsA or plaque psoriasis that would interfere with assessment of study parameters, as per judgement of investigator
- •NOTE: Prior history of reactive arthritis or axial spondyloarthritis is permitted if there is documentation of change in diagnosis to PsA or additional diagnosis of PsA
- •Any history of an inflammatory arthropathy with onset before age of 16 years old
- •Active autoimmune disease other than those listed above, that would interfere with assessment of study parameters or increase risk to the subject by participating in the study, (e.g. uveitis, inflammatory bowel disease, uncontrolled thyroiditis, systemic vasculitis,
- •transverse myelitis), per judgement of investigator
- •Pregnancy or nursing females
- •Active drug or alcohol abuse, as per judgement of investigator
结局指标
主要结局
ACR20 response
时间窗: Week 12
To evaluate the effect of filgotinib compared to placebo in active psoriatic arthritis (PsA) as assessed by the American College of Rheumatology 20% improvement (ACR20) response
次要结局
- Minimal Disease Activity (MDA) and Very Low Disease Activity (VLDA), ACR responses, PASI including BSA responses, SPARCC Enthesitis Index and LEI, LDI, PASDAS, DAPSA, mNAPSI, and PhGAP
- HAQ-DI
- FACIT Fatigue, SF 36v2, and PsAID 12
- safety and tolerability of filgotinib
研究者
研究点 (1)
Loading locations...
相似试验
终止
4 期
A Prospective Study on Efficacy and Safety of Filgrastim (Leuco-Plus 300) for Prevention of Chemotherapy Induced Neutropenia in Patients with Diffuse Large B-Cell LymphomaPatients with Diffuse Large B-Cell LymphomaCHOPR-DLBCLTCTR20170802002Apexcela Co., Ltd.20
已完成
4 期
A Pilot Study to Evaluate Efficacy and Safety of Fixed Dose Combination Capsules in Patients with GERD and Overlapping Symptoms of DyspepsiaCTRI/2020/09/027876Abbott India limited50
已完成
不适用
Evaluation of the efficacy and safety of luseogliflozin and changes in QOType 2 diabetes mellitusJPRN-UMIN000023035The Institute for Adult Diseases, Asahi Life Foundation64
已完成
不适用
Validation study of the efficacy and safety of first precutting for Oral protrusion-Large, which is difficult to biliary duct cannulation.Cases requiring ERCPJPRN-UMIN000042805Kitasato University School of Medicine38
进行中（未招募）
不适用
Clinical study to assess the efficacy and safety of GFT505 80 mg and GFT505 120 mg daily for 52 weeks in Patients with Non-Alcoholic Steatohepatitis (accumulation of fat in the liver associated with inflammation and liver cell injury at microscopic examination of liver biopsy).EUCTR2012-000295-42-ITGENFIT SA270